These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 33808155)
21. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ). Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650 [TBL] [Abstract][Full Text] [Related]
22. The Hippo-YAP/TAZ Signaling Pathway in Intestinal Self-Renewal and Regeneration After Injury. Deng F; Wu Z; Zou F; Wang S; Wang X Front Cell Dev Biol; 2022; 10():894737. PubMed ID: 35927987 [TBL] [Abstract][Full Text] [Related]
23. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857 [TBL] [Abstract][Full Text] [Related]
24. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis. Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452 [TBL] [Abstract][Full Text] [Related]
25. Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma. Lamar JM; Motilal Nehru V; Weinberg G Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29996478 [TBL] [Abstract][Full Text] [Related]
26. Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective. Samji P; Rajendran MK; Warrier VP; Ganesh A; Devarajan K Cell Signal; 2021 Feb; 78():109858. PubMed ID: 33253912 [TBL] [Abstract][Full Text] [Related]
27. Identification of PTPN12 Phosphatase as a Novel Negative Regulator of Hippo Pathway Effectors YAP/TAZ in Breast Cancer. Sarmasti Emami S; Ge A; Zhang D; Hao Y; Ling M; Rubino R; Nicol CJB; Wang W; Yang X Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612874 [TBL] [Abstract][Full Text] [Related]
28. The regulation of yes-associated protein/transcriptional coactivator with PDZ-binding motif and their roles in vascular endothelium. Zhang W; Li QQ; Gao HY; Wang YC; Cheng M; Wang YX Front Cardiovasc Med; 2022; 9():925254. PubMed ID: 35935626 [TBL] [Abstract][Full Text] [Related]
29. The Hippo signaling pathway provides novel anti-cancer drug targets. Bae JS; Kim SM; Lee H Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075 [TBL] [Abstract][Full Text] [Related]
30. YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Lo Sardo F; Strano S; Blandino G Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29734788 [TBL] [Abstract][Full Text] [Related]
31. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness. Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565 [No Abstract] [Full Text] [Related]
32. Hippo/TEAD4 signaling pathway as a potential target for the treatment of breast cancer. Wu Y; Li M; Lin J; Hu C Oncol Lett; 2021 Apr; 21(4):313. PubMed ID: 33692845 [TBL] [Abstract][Full Text] [Related]
33. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692 [TBL] [Abstract][Full Text] [Related]
34. Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. Grijalva JL; Huizenga M; Mueller K; Rodriguez S; Brazzo J; Camargo F; Sadri-Vakili G; Vakili K Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G196-204. PubMed ID: 24875096 [TBL] [Abstract][Full Text] [Related]
35. YAP/TAZ: Molecular pathway and disease therapy. Wei Y; Hui VLZ; Chen Y; Han R; Han X; Guo Y MedComm (2020); 2023 Aug; 4(4):e340. PubMed ID: 37576865 [TBL] [Abstract][Full Text] [Related]
36. Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension. Xu Q; Zhuo K; Cai R; Su X; Zhang L; Liu Y; Zhu L; Ren F; Zhou MS Front Physiol; 2021; 12():732084. PubMed ID: 34650444 [TBL] [Abstract][Full Text] [Related]
37. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005 [TBL] [Abstract][Full Text] [Related]
38. Hippo Signaling in Cancer: Lessons From Snigdha K; Gangwani KS; Lapalikar GV; Singh A; Kango-Singh M Front Cell Dev Biol; 2019; 7():85. PubMed ID: 31231648 [TBL] [Abstract][Full Text] [Related]
39. LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer. Zhu B; Finch-Edmondson M; Leong KW; Zhang X; V M; Lin QXX; Lee Y; Ng WT; Guo H; Wan Y; Sudol M; DasGupta R Cell Death Discov; 2021 Nov; 7(1):369. PubMed ID: 34845189 [TBL] [Abstract][Full Text] [Related]
40. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer. Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP Front Surg; 2022; 9():813123. PubMed ID: 35388363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]